The global Tumor Ablation Market is growing as healthcare providers increasingly adopt minimally invasive approaches for treating localized tumors. Tumor ablation uses technologies such as radiofrequency, microwave, cryoablation, and high-intensity focused ultrasound to destroy tumor tissue while potentially reducing recovery time, pain, and hospital stay compared with some conventional surgical approaches. Rising cancer incidence, increasing use of image-guided procedures, and technological advances in ablation systems are supporting market growth.

According to Fortune Business Insights, the global tumor ablation market was valued at USD 846.8 million in 2025 and is projected to grow from USD 903.3 million in 2026 to USD 1,579.7 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

Why is the Tumor Ablation Market Growing?

The increasing prevalence of cancer and other chronic conditions is a major factor driving demand for tumor ablation procedures. Patients with localized tumors, as well as some patients who may not be ideal candidates for major surgery, can be treated with minimally invasive ablation approaches.

Tumor ablation is increasingly used in:

• Liver cancer
• Lung cancer
• Kidney cancer
• Bone tumors
• Localized solid tumors
• Recurrent tumors
• Patients requiring minimally invasive treatment

The advantages associated with ablation, including shorter recovery periods, reduced pain, and shorter hospital stays, are further supporting adoption.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Microwave Ablation

The Microwave Ablation segment dominated the market in 2025 and is expected to account for 34.9% of the market in 2026. Increasing procedure volumes and continued product development are supporting the segment.

In January 2024, Hygea (Beijing) Medical Technology Co., Ltd. received U.S. FDA approval for its EXCEED microwave treatment system and EXACT series microwave ablation probes, supporting the expansion of microwave-based treatment technologies.

Growing Use of Percutaneous Procedures

The Percutaneous treatment segment held a dominant 68.1% share in 2025. The growth is supported by increasing use of minimally invasive procedures for cancers such as lung and liver cancer.

Percutaneous ablation can be performed using image guidance, allowing physicians to target tumors through small access points rather than requiring extensive surgical intervention.